



## **EUSA Pharma (UK) Ltd Modern Slavery Act Statement 2019**

Pursuant to Section 54 of the UK Modern Slavery Act 2015 (“Act”), EUSA Pharma (UK) Ltd and its subsidiaries (“EUSA”) are committed to preventing slavery and human trafficking in its business and supply chains. We acknowledge our responsibilities under the Act and are continuing to take measures to ensure our business and supply chain are free from modern slavery. We provide the following statement to set out the steps taken by EUSA during the financial year ending 31<sup>st</sup> December 2019 to prevent modern slavery and human trafficking in our business and supply chains.

### **EUSA’s Structure**

EUSA Pharma (UK) Ltd is based in the UK with subsidiary companies based in France, Germany, Spain, Italy, the Netherlands, Denmark, Switzerland, Australia and the USA.

### **EUSA’s Business**

EUSA is a growing global biopharmaceutical company focused on oncology and rare disease.

### **EUSA’s Supply Chains**

Our supply chains include 1) the manufacture and supply of active pharmaceutical ingredients and excipients for pharmaceutical products; 2) the manufacture and packaging of finished pharmaceutical products; and 3) the promotion, sale and distribution of finished pharmaceutical products globally.

EUSA takes its responsibility seriously and regularly reviews its measures in its supply chain in relation to human rights, ethical conduct and personal data protection. EUSA requires all of its suppliers to subscribe to its Code of Conduct and ethics, and to formally agree to maintaining compliance with all applicable laws relating to safety, health, environment, competition and anti-trust, human rights, fair labour practices, unlawful discrimination and anti-bribery/anti-corruption.

### **Actions taken**

EUSA has:

- Continued to carry out due diligence checks on current suppliers in our manufacturing business globally with emphasis on modern slavery practices.
- Continued to ask anti-modern slavery compliance questions in our due diligence questionnaire used for new third parties we engage with.
- Implemented an Anti-Slavery and Human Trafficking Policy across the business.
- Implemented annual training for its management and employees across the business through an e-learning platform.
- Updated our Code of Conduct to ensure we continue to conduct business with the highest standards of ethics.
- Implemented an ethics hotline to facilitate the reporting of any modern slavery concerns our employees or third parties may have.



- Updated our partner distribution contract templates to include clauses around anti-modern slavery and human trafficking in high risk jurisdictions. Such clauses are in the process of being implemented across all relevant distribution agreements.

This Statement has been approved by the Board of Directors and EUSA Pharma (UK) Ltd as of 17<sup>th</sup> December 2020

A handwritten signature in blue ink, appearing to read "Lee Morley", written over a horizontal line.

Name: Lee Morley

Title: CEO/Director

Date: 17<sup>th</sup> December 2020

A handwritten signature in blue ink, appearing to read "Emma Johnson", written over a horizontal line.

Name: Emma Johnson

Title: CFO/Director

Date: 17<sup>th</sup> December 2020

A handwritten signature in blue ink, appearing to read "Dev Kumar", written over a horizontal line.

Name: Dev Kumar

Title: VP – Head of Legal & Compliance/Director

Date: 17<sup>th</sup> December 2020